Market Data 
Markets
Replies to post #197594 on NorthWest Biotherapeutics Inc (NWBO)
"Recent information suggests that patients mounting immune responses after immunotherapy can recognize novel neoantigens created by tumor-specific mutations. Our hypothesis is that glioblastoma patients treated with autologous tumor lysate-pulsed DC vaccination will mount anti-tumor immune responses against specific mutations in their individual tumor. Furthermore, we hypothesize that patients with extended survival will have mounted more diverse anti-tumor immune responses to such neoantigens." -- Immunotherapeutic targeting of the Glioblastoma Mutanome
Prins, Robert M. Largaespada, David Andrew
University of California Los Angeles, Los Angeles, CA, United States
grantome.com/grant/NIH/R21-CA186004-01A1
Project End. December 2016.
11/15/18 5:54 PM
With neoantigens there is no pre-existing tolerance and minimal risk of autoimmunity.
11/15/18 8:12 PM
AI
